Health Canada Authorizes Lilly’s Lebrikizumab for the Treatment of AD
Health Canada has authorized lebrikizumab (Ebglyss, Eli Lilly Canada Inc), a targeted interleukin (IL)-13 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and adolescents 12 years of age and older with a body weight of at least 40kg, whose disease is not well controlled despite treatment with topical prescription therapies or when […]